Molecular Cancer Therapeutics Landon Prizes for Basic and Translational Cancer Research Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Han, S.
Right arrow Articles by Roman, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Han, S.
Right arrow Articles by Roman, J.
Mol Cancer Ther. 2006;5:430-437
© 2006 American Association for Cancer Research

Rosiglitazone suppresses human lung carcinoma cell growth through PPAR{gamma}-dependent and PPAR{gamma}-independent signal pathways

ShouWei Han1 and Jesse Roman1,2

1 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Emory University School of Medicine and 2 Atlanta Veterans Affairs Medical Center, Atlanta, Georgia

Requests for reprints: ShouWei Han, Division of Pulmonary, Allergy, and Critical Care Medicine, Emory University School of Medicine, Whitehead Bioresearch Building, 615 Michael Street, Suite 205-M, Atlanta, GA 30322. Phone: 404-712-2661; Fax: 404-712-2151. E-mail: shan2{at}emory.edu


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Peroxisome proliferator-activated receptors {gamma} (PPAR{gamma}) exert diverse effects on cancer cells. Recent studies showed that rosiglitazone, a synthetic ligand for PPAR{gamma}, inhibits cell growth. However, the exact mechanisms underlying this effect are still being explored, and the relevance of these findings to lung cancer remains unclear. Here, we report that rosiglitazone reduced the phosphorylation of Akt and increased phosphatase and tensin homologue (PTEN) protein expression in non–small cell lung carcinoma (NSCLC) cells (H1792 and H1838), and this was associated with inhibition of NSCLC cell proliferation. These effects were blocked or diminished by GW9662, a specific PPAR{gamma} antagonist. However, transfection with a CMX-PPAR{gamma}2 overexpression vector restored the effects of rosiglitazone on Akt, PTEN, and cell growth in the presence of GW9662. In addition, rosiglitazone increased the phosphorylation of AMP-activated protein kinase {alpha} (AMPK{alpha}), a downstream kinase target for LKB1, whereas it decreased phosphorylation of p70 ribosomal protein S6 kinase (p70S6K), a downstream target of mammalian target of rapamycin (mTOR). Of note, GW9662 did not affect the phosphorylation of AMPK{alpha} and p70S6K protein. The inhibitory effect of rosiglitazone on NSCLC cell growth was enhanced by the mTOR inhibitor rapamycin; however, it was blocked, in part, by the AMPK{alpha} small interfering RNA. Taken together, these findings show that rosiglitazone, via up-regulation of the PTEN/AMPK and down-regulation of the Akt/mTOR/p70S6K signal cascades, inhibits NSCLC cell proliferation through PPAR{gamma}-dependent and PPAR{gamma}-independent signals. [Mol Cancer Ther 2006;5(2):430–7]


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Peroxisome proliferator-activated receptors (PPAR; isotypes {alpha}, ß/{delta}, and {gamma}) are ligand-inducible nuclear transcription factors (1). PPARs heterodimerize with retinoid X receptors (2) and bind to PPAR response elements located in the promoter region of PPAR target genes. These lipid-sensitive receptors can be activated in a variable isotype-specific manner by natural fatty acids, leukotrienes, prostaglandins, and some synthetic agonists, including antidiabetic drugs, such as rosiglitazone, ciglitazone, and pioglitazone. These drugs are also effective in regulating cell activation, differentiation, proliferation, and/or apoptosis (3, 4).

The role of PPAR{gamma}, one PPAR isotype, has been extensively studied during the past several years. Synthetic PPAR{gamma} agonists specifically bind to PPAR{gamma} isoforms, and induce its activity, which in turn, results in altered expression of PPAR{gamma} target genes. The efficacy of these compounds as anticancer agents has been examined in a variety of cancers, including colon, breast, and prostate (5). PPAR{gamma} expression has also been shown in non–small cell lung carcinoma (NSCLC) cells and was correlated with tumor histologic type and grade (6). Activation of PPAR{gamma} by troglitazone, ciglitazone, and pioglitazone caused growth inhibition and apoptosis of NSCLC cells (7, 8). Recently, studies in animal models of tumorigenesis showed that treatment of A549 tumor-bearing severe combined immunodeficient mice with troglitazone or pioglitazone inhibited primary tumor growth by 66.7% and significantly inhibited the number of spontaneous lung metastatic lesions. These observations suggest that PPAR{gamma} ligands may serve as potential therapeutic agents in the management of NSCLC (9).

Thus far, the mechanisms by which PPAR{gamma} ligands suppress NSCLC cell growth have not been fully elucidated. Here, we explore the effects of the PPAR{gamma} ligand rosiglitazone on NSCLC proliferation, and how its effects might relate to the activation of the phosphatidylinositol 3-kinase (PI3K)/Akt and the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR)/p70 ribosomal S6 kinase (p70S6K) pathways. PI3K is a heterodimeric enzyme involved in the regulation of mitogenesis, apoptosis, cell adhesion, and motility (10). This enzyme has been suggested as a proto-oncogene in human cancer. mTOR has been shown to be a key kinase acting downstream of the activation of the PI3K, through which it regulates an array of cellular processes. Signaling via mTOR controls cell size and growth as well as other functions, and this pathway represents a potential therapeutic target in graft rejection, certain cancers, and disorders characterized by inappropriate cell or tissue growth (11). mTOR signaling induced by hormones or growth factors and amino acids regulates the phosphorylation of several proteins, including p70S6K and eIF-4E binding protein (4E-BP1), which are key regulators of translation, and are among the most well characterized targets of mTOR (12). This pathway is down-regulated by AMPK and the tumor suppressor LKB1 (13–18), which is an upstream signal of mTOR. AMPK is the central component of a protein kinase cascade that plays a key role in the regulation of energy control. Several findings point to a link between AMPK and the growth and/or survival of some cancer cells (14, 15). It has been shown that the tumor suppressor LKB1 is a kinase that has a major role in phosphorylating and activating AMPK (13). In addition, other studies indicate that mammalian homologue of mTOR, which has been implicated in the pathogenesis of insulin resistance and many types of cancer, is inhibited by AMPK (14).

We found that rosiglitazone inhibited the Akt/mTOR/p70S6K pathway and stimulated phosphatase and tensin homologue (PTEN) and AMPK signals in NSCLC cells through PPAR{gamma}-dependent and PPAR{gamma}-independent pathways. These events were responsible for the growth-inhibitory effects of rosiglitazone.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Culture and Chemicals
The human NSCLC cell lines H1838 and H1792 were obtained from the American Type Culture Collection (Manassas, VA) and grown in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, HEPES buffer, 50 IU/mL penicillin/streptomycin, and 1 µg amphotericin (complete medium) as previously described (19). Rapamycin and polyclonal antibodies specific for PTEN, AMPK{alpha}, p70S6K, Akt, and their respective phosphorylated active forms were purchased from Cell Signaling (Beverly, MA). GW9662, rosiglitazone, and all other chemicals were purchased from Sigma Aldrich (St. Louis, MO), unless otherwise indicated.

Transient Transfection with a CMX-PPAR{gamma}2 Plasmid Construct
The CMX-PPAR{gamma}2 overexpression vector was obtained from Dr. Neil Sidell (Department of Gynecology and Obstetrics, Emory University, Atlanta, GA) and has been described previously (20). For functional studies, H1792 cells were seeded at a density of 1 x 105 per well in six-well dishes and grown to 60% confluence. For each well, the plasmid DNA containing CMX-PPAR{gamma}2 (1.3 µg/mL) was transfected into cells using FUGENE 6 lipofection reagent as described in our earlier work (21). Control cells were transfected with FUGENE 6 lipofection reagent only. After 24 hours of incubation, cells were treated with or without GW9662 (20 µmol/L) for 1 hour before exposing the cells to rosiglitazone (10 µmol/L) in the presence or absence of 1 µCi/mL [methyl-3H]thymidine (Amersham, Arlington Heights, IL; specific activity = 250 Ci/mmol) for an additional 24 hours. Afterwards, the cells were processed for Western blot analysis and the [methyl-3H]thymidine incorporation assay as described below.

Western Blot Analysis
The procedure was done as previously described (22). Briefly, protein concentrations were determined by the Bio-Rad protein assay. Equal amounts of protein from whole-cell lysates were solubilized in 2x SDS-sample buffer and separated on SDS/8% polyacrylamide gels. Blots were incubated with antibodies raised against AMPK{alpha} and phosphorylated AMPK{alpha}, p70S6K and phosphorylated p70S6K, Akt and its activated form, and PTEN (1:1,000). The blots were washed and followed by incubation with a secondary goat antibody raised against rabbit IgG conjugated to horseradish peroxidase (1:2,000; Cell Signaling). The blots were washed, transferred to freshly made enhanced chemiluminescence solution (Amersham) for 1 minute, and exposed to X-ray film. In controls, the antibodies were omitted or replaced with a control rabbit IgG.

Treatment with AMPK Small Interfering RNA
The AMPK{alpha} small interfering RNA (siRNA, ID no. 772) was purchased from Ambion (Austin, TX). Nonspecific control siRNA was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). For the transfection procedure, cells were grown to 50% confluence, and AMPK{alpha} or control siRNAs were transfected using the LipofectAMINE 2000 reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Briefly, oligofectamine reagent was incubated with serum-free medium for 10 minutes. Subsequently, a mixture of siRNA was added. After incubation for 15 minutes at room temperature, the mixture was diluted with medium and added to each well. The final concentration of siRNA in each well was 100 nmol/L. After culturing for 48 hours, cells were washed and resuspended in new culture media in the presence or absence of rosiglitazone for up to 48 hours for Western blot and cell growth assays.

[Methyl-3H]Thymidine Incorporation Assay
Human lung carcinoma cells (104 per well) were cultured with GW9662 (20 µmol/L) for 1 hour or transfected with AMPK{alpha} siRNA (100 nmol/L) for 48 hours before exposing the cells to rosiglitazone (10 µmol/L) or rapamycin (10 nmol/L) followed by incubation with 1 µCi/mL [methyl-3H]thymidine (Amersham; specific activity = 250 Ci/mmol) for up to 48 hours. The medium was removed, and the attached cells were washed with 1x PBS. Afterwards, the attached cells were treated with ice-cold 6% trichloroacetic acid at 4°C for 20 minutes and washed once with 6% trichloroacetic acid. The cells were then solubilized with 0.1 N NaOH and counted in a liquid scintillation counter in 4 mL of scintillation fluid.

Statistical Analysis
All experiments were repeated a minimum of three times. All data collected from Western blot and [methyl-3H]thymidine incorporation assays were expressed as means ± SD. The data presented in some figures are from a representative experiment, which was qualitatively similar in the replicate experiments. Statistical significance was determined with Student's t test (two tailed) comparison between two groups of data sets. Asterisks shown in the figures indicate significant differences of experimental groups compared with the corresponding control condition (P < 0.05; see figure legends).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Rosiglitazone Inhibits the Phosphorylation of Akt Protein in a Dose-Dependent and Time-Dependent Manner
The PI3K/Akt signal pathway has been implicated in the regulation of cell cycle progression and cell proliferation. In certain cell types (e.g., human embryonic kidney 293 cells and intestinal epithelial cells), this pathway was blocked by rosiglitazone (23, 24). Therefore, we tested the effects of rosiglitazone in NSCLC cells. We found that rosiglitazone reduced the phosphorylation of the PI3K downstream signal Akt in a time-dependent and dose-dependent manner with maximal reduction at 10 µmol/L for 3 hours, whereas no effects were noted in total Akt protein (Fig. 1A-B ). Conversely, rosiglitazone stimulated the expression of PTEN protein in a dose-dependent and time-dependent manner with a most effective dose of 10 µmol/L at 24 hours; higher concentrations had no further effect (Fig. 1C-D). Similar results were obtained in H1838 cells (data not shown).


Figure 1
View larger version (24K):
[in this window]
[in a new window]
  		Figure 1. The effect of rosiglitazone on Akt phosphorylation and PTEN protein expression. A, rosiglitazone inhibition of Akt phosphorylation is dose dependent. Cellular protein was isolated from H1792 cells that were cultured with increasing concentrations of rosiglitazone for up to 24 h. Then, Western blot analysis was done using antibodies against phosphorylated Akt (p-Akt) and total Akt. B, rosiglitazone inhibition of Akt phosphorylation is time dependent. Cellular protein was isolated from H1792 cells that were cultured with rosiglitazone (10 µmol/L) for indicated periods of time followed by Western blot analysis with antibodies against phosphorylated Akt and total Akt protein. C, rosiglitazone stimulation of PTEN is dose dependent. Cellular protein was isolated from H1792 cells that were cultured with increasing concentrations of rosiglitazone for up to 24 h followed by Western blot analysis with antibodies against PTEN. D, rosiglitazone stimulation of PTEN is time dependent. Cellular protein was isolated from H1792 cells that were cultured with rosiglitazone (10 µmol/L) for indicated period of time followed by Western blot analysis with antibodies against PTEN protein. Actin served as internal control for normalization purposes. Columns, mean of phosphorylated Akt or PTEN/actin of at least three independent experiments; bars, SD. *, P < 0.05, significant differences compared with untreated cells.

 
Rosiglitazone Inhibits Akt Phosphorylation and Stimulates PTEN Expression through PPAR{gamma}
Rosiglitazone has been shown to activate PPAR{gamma} in several studies (7, 8, 25, 26). Therefore, we tested whether the effects of rosiglitazone on Akt and PTEN were mediated through the activation of PPAR{gamma} by treating the cells with GW9662, a specific PPAR{gamma} antagonist. As shown in Fig. 2A , the effects of rosiglitazone on Akt phosphorylation and PTEN expression were eliminated in the presence of GW9662. However, cells transfected with a PPAR{gamma} overexpression vector showed restoration of the effect of rosiglitazone on AKT and PTEN expression. These findings suggest that PPAR{gamma}-dependent signals mediate the effect of rosiglitazone on Akt and PTEN.


Figure 2
View larger version (27K):
[in this window]
[in a new window]
  		Figure 2. PPAR{gamma}-dependent signal pathways mediate the effects of rosiglitazone on phosphorylation of Akt and PTEN protein expression and on lung carcinoma cell growth. A, PPAR{gamma}-dependent signal pathways mediate the effects of rosiglitazone on phosphorylation of Akt and PTEN protein expression. Cellular protein was isolated from H1792 cells transfected with CMX-PPAR{gamma}2 vector using FUGENE 6 lipofection reagent for 24 h. After transfection, cells were cultured for 1 h in the presence or absence of GW9662 (20 µmol/L) before exposing the cells to rosiglitazone (10 µmol/L) for an additional 24 h, then subjected to Western blot analysis with antibodies against phosphorylated Akt (p-Akt), total Akt, PTEN, and actin. Columns, mean of at least three independent experiments; bars, SD. Actin served as internal control for normalization purposes. *, P < 0.05, significant differences compared with untreated cells. B, rosiglitazone inhibits cell growth in a dose-dependent manner. H1792 cells were treated with increasing concentrations of rosiglitazone followed by incubation with 1 µCi/mL [methyl-3H]thymidine for up to 48 h and cell number determination. C, effects of rosiglitazone on cell growth are mediated through PPAR{gamma} signals. H1792 cells were transfected with or without CMX-PPAR{gamma}2 vector using FUGENE 6 lipofection reagent for 24 h. Afterwards, the cells were treated with or without GW9662 (20 µmol/L) for 1 h before exposing the cells to rosiglitazone (10 µmol/L) and incubation with 1 µCi/mL [methyl-3H]thymidine for up to 48 h and cell number determination. *, P < 0.05, significant differences compared with the untreated cells. **, P < 0.05, significance of combination treatment compared with rosiglitazone alone. ***, significance of combination treatment compared with rosiglitazone plus GW9662. Con, untreated cells.

 
To evaluate the relevance of the above findings to NSCLC proliferation, we treated NSCLC cells with rosiglitazone and evaluated proliferation. We found that rosiglitazone inhibited the proliferation of NSCLC cells in a dose-dependent manner (Fig. 2B). The inhibitory effect of rosiglitazone was diminished by the PPAR{gamma} antagonist GW9662 (Fig. 2C). Cells transfected with the PPAR{gamma} overexpression vector antagonized the effect of GW9662 on cell growth (Fig. 2C). Of note, GW9662 only inhibited the effect of rosiglitazone partially suggesting that PPAR{gamma}-independent signals were also involved. Similar results were obtained in H1838 cells (data not shown).

Rosiglitazone Induces AMPK Phosphorylation and Inhibits p70S6K Phosphorylation through PPAR{gamma}-Independent Signals
We then investigated the potential PPAR{gamma}-independent signals that mediate the effects of rosiglitazone on NSCLC cell proliferation. We focused our attention on the mTOR pathway. We started by examining the effect of rosiglitazone on AMPK, an upstream modulator of mTOR. As shown in Fig. 3A and B , rosiglitazone induced the phosphorylation of AMPK{alpha} protein in a dose-dependent and time-dependent manner, whereas it had no effect on total content of AMPK{alpha} protein as determined by Western blot analysis in H1792 cells. However, rosiglitazone had no effects on LKB1, an upstream signal of AMPK (data not shown). Similar results were obtained in H1838 cells (data not shown).


Figure 3
View larger version (44K):
[in this window]
[in a new window]
  		Figure 3. Effects of rosiglitazone on AMPK protein. A, rosiglitazone stimulation of AMPK{alpha} phosphorylation is dose dependent. Cellular protein was isolated from H1792 cells that were cultured with increasing concentrations of rosiglitazone for up to 24 h. Afterwards, Western blot analysis was done using antibodies against phosphorylated AMPK{alpha} (pAMPK{alpha}) and total AMPK{alpha}. B, rosiglitazone stimulation of AMPK{alpha} phosphorylation is time dependent. Cellular protein was isolated from H1792 cells that were cultured with rosiglitazone (10 µmol/L) for indicated periods of time followed by Western blot analysis with antibodies against phosphorylated AMPK{alpha} and total AMPK{alpha} protein. Actin served as internal control for normalization purposes. Columns, mean of AMPK/actin of at least three independent experiments; bars, SD. *, P < 0.05, significant differences compared with the untreated cells.

 
We next assessed the effects on p70S6K, a downstream target of mTOR, and found that rosiglitazone affected the expression of p70S6K. As shown in Fig. 4 , H1792 cells exposed to the indicated concentrations of rosiglitazone showed a decrease in the phosphorylation of p70S6K protein in a dose-dependent (A) and time-dependent (B) manner with effective inhibition at 10 µmol/L rosiglitazone in 24 hours, whereas it had no effect on total content of p70S6K. Similar results were obtained in H1838 (data not shown).


Figure 4
View larger version (26K):
[in this window]
[in a new window]
  		Figure 4. Effect of rosiglitazone on p70S6K protein. A, rosiglitazone inhibition of p70S6K phosphorylation is dose dependent. Cellular protein was isolated from H1792 cells that were cultured with increasing concentrations of rosiglitazone for up to 24 h. Afterwards, Western blot analysis was done using antibodies against phosphorylated p70S6K (p-p70S6K) and total p70S6K. B, rosiglitazone inhibition of p70S6K phosphorylation is time dependent. Cellular protein was isolated from H1792 cells that were cultured with rosiglitazone (10 µmol/L) for indicated period of time followed by Western blot analysis with antibodies against phosphorylated p70S6K and total p70S6K protein. Actin served as internal control for normalization purposes. Columns, mean of phosphorylated p70S6K/actin of at least three independent experiments; bars, SD. *, P < 0.05, significant differences compared with the untreated cells.

 
To examine whether the effects of rosiglitazone on AMPK and p70S6K phosphorylation were mediated through PPAR{gamma}, we inactivated PPAR{gamma} with GW9662. As shown in Fig. 5A , GW9662 did not block the effects of rosiglitazone on either AMPK or p70S6K phosphorylation, indicating that these effects were PPAR{gamma} independent. In view that rosiglitazone regulated mTOR-related proteins AMPK and p70S6K, we tested whether the mTOR inhibitor rapamycin influenced the NSCLC growth inhibition induced by rosiglitazone. As shown in Fig. 5B, rapamycin reduced NSCLC cell growth and further enhanced cell growth inhibition in the presence of rosiglitazone. In contrast to its effects on rosiglitazone-mediated cell growth inhibition, GW9662 did not block the effect of rapamycin on NSCLC cell growth reduction, suggesting that the inhibition of cell proliferation by rosiglitazone and rapamycin was mediated through different pathways. Similar results were obtained in H1838 cells (data not shown).


Figure 5
View larger version (35K):
[in this window]
[in a new window]
  		Figure 5. PPAR{gamma}-independent signal pathways mediate the effects of rosiglitazone on AMPK and p70S6K expression and on lung carcinoma cell growth. A, PPAR{gamma}-independent signal pathways mediate the effects of rosiglitazone on protein expression. Cellular protein was isolated from H1792 cells cultured for 1 h in the presence or absence of GW9662 (20 µmol/L) before exposing the cells to rosiglitazone (10 µmol/L) for an additional 24 h, then subjected to Western blot analysis with antibodies against phosphorylated AMPK{alpha} (p-AMPK{alpha}), total AMPK, phosphorylated p70S6K (p-p70S6K), total p70S6K, and actin. Columns, mean of at least three independent experiments; bars, SD. Actin served as internal control for normalization purposes. B, effects of rapamycin on cell growth are not mediated by PPAR{gamma} signals. H1792 cells were cultured with GW9662 (20 µmol/L) for 1 h before exposing the cells to rapamycin (10 nmol/L) and incubated with 1 µCi/mL [methyl-3H]thymidine for up to 48 h. Afterwards, the cells numbers were determined. *, P < 0.05, significance of combination treatment compared with rosiglitazone alone. **, P < 0.05, significance of combination treatment compared with rapamyicn alone. Con, untreated cells.

 
Blocking the AMPK Signal Abrogated, in Part, the Effect of Rosiglitazone on Cell Growth Inhibition
Because rosiglitazone activated the phosphorylation of AMPK, we therefore determined whether blocking the expression of AMPK could affect the inhibitory effect of rosiglitazone on cell growth. We first depleted AMPK{alpha} expression in cells using the small RNA interference method. As shown in Fig. 6A , AMPK{alpha} siRNA greatly diminished endogenous AMPK{alpha} protein production; no changes were noted in cells transfected with control siRNA. Next, H1792 cells were transfected with AMPK siRNA. Afterwards, the cells were exposed to rosiglitazone for an additional 48 hours followed by evaluation of cell proliferation by thymidine incorporation assay. As shown in Fig. 6B, AMPK siRNA significantly abrogated rosiglitazone-reduced cell proliferation; the control siRNA had no effect. This suggests that activation of AMPK also plays a role in mediating the effect of rosiglitazone on NSCLC cell growth inhibition. Similar results were obtained in H1838 cells (data not shown).


Figure 6
View larger version (26K):
[in this window]
[in a new window]
  		Figure 6. AMPK stimulation contributes to the effect of rosiglitazone on cell growth. A, AMPK{alpha} siRNA inhibits AMPK{alpha} protein expression. Cellular protein was isolated from H1792 cells transfected with control or AMPK siRNA (100 nmol/L) for 48 h then subjected to Western blot analysis for AMPK protein. B, AMPK siRNA ameliorates the inhibitory effect of rosiglitazone on cell growth. H1792 cells were transfected with control or AMPK siRNA (100 nmol/L each) for 48 h before exposing the cells to rosiglitazone (10 µmol/L) and incubation with 1 µCi/mL [methyl-3H]thymidine for up to 48 h. Afterwards, the cells numbers were determined. *, P < 0.05, significant differences compared with the untreated cells. **, P < 0.05, significance of combination treatment compared with rosiglitazone alone. Con, untreated cells.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Rosiglitazone, one of the thiazolidinedione derivatives, is the most potent and selective synthetic ligand of PPAR{gamma}. It binds to PPAR{gamma} with a Kd of ~40 nmol/L and is known to have marked adipogenic effects on preadipocyte and mesenchymal stem cells in vitro and to have dramatic antidiabetic effects (27). In this study, we showed that rosiglitazone inhibits human lung carcinoma cell growth in vitro. These effects were dose dependent, and the concentrations used here were consistent with those reported by others. For example, Valentiner et al. found that rosiglitazone inhibited in vitro growth and viability of human neuroblastoma cell lines in a dose-dependent manner, showing considerable effects only at high concentrations (10 and 100 µmol/L; ref. 28). In another study, rosiglitazone inhibited both the proliferation and invasiveness of the human adrenocortical cancer cell line H295R in a dose-dependent manner with the maximal effect (about 50% inhibition) obtained at 20 µmol/L (26).

The mechanisms responsible for the effects of rosiglitazone seem to involve both PPAR{gamma}-dependent and PPAR{gamma}-independent signals. Specifically, we found that rosiglitazone inhibited the phosphorylation of the downstream signal of PI3K, Akt, and increased PTEN expression in NSCLC cells. These changes were inhibited by GW9662, suggesting that they depend upon PPAR{gamma} activation. The PI3K/Akt signaling axis plays an important role in cellular proliferation and growth signaling (23). Akt, also known as protein kinase B, is a critical enzyme in several signal transduction pathways that regulate cell survival, growth, differentiation, angiogenesis, migration, and metabolism. This pathway is frequently altered in human malignancies, and overexpression of Akt induces malignant transformation and chemoresistance (29). Thus, the Akt pathway is a major target for anticancer drug development. Consistent with our data, rosiglitazone has been shown to inhibit the phosphorylation of Akt in several cell systems, including other cancer cells (22, 30, 31). Thus, suppression of Akt signaling may represent one mechanism for the observed NSCLC cell growth inhibition induced by rosiglitazone.

Rosiglitazone also stimulated the expression of PTEN. This tumor suppressor is a dual-specific phosphatase that plays a functional role in cell cycle arrest and apoptosis (32). Strong evidence indicates that loss of PTEN drives tumor development through deregulation of the PI3K/Akt signal pathway, thereby inhibiting cell growth and survival (33). Consistent with our data, the stimulatory effect of rosiglitazone on PTEN has been shown in other cancer cells (31, 33, 34). For example, Farrow et al. (31) showed that rosiglitazone increased PTEN expression in pancreatic cancer cells, and the levels of phosphorylated Akt decreased as PTEN levels increased, indicating inhibition of PI3K activity.

The PPAR{gamma} antagonist GW9662 abolished the effects of rosiglitazone on phosphorylation of Akt and PTEN expression, suggesting that PPAR{gamma} mediated, at least in part, the effects of rosiglitazone. Rosiglitazone has been shown to inhibit the growth of several human cancer cells through PPAR{gamma}-dependent signals (26, 35, 36). Ferruzzi et al. (26) found that rosiglitazone inhibited the growth and invasiveness of human adrenocortical cancer cells through activation of PPAR{gamma}. Results obtained with the CMX-PPAR{gamma} overexpression vector further suggest the involvement of PPAR{gamma}-dependent signals in mediating the effects of rosiglitazone on AKT and PTEN expression and cell growth inhibition.

As stated above, we found that GW9662 abrogated the effects of rosiglitazone on cell growth. However, GW9662 did not completely block the effects of rosiglitazone suggesting the involvement of PPAR{gamma}-independent signals. Rosiglitazone has been shown to activate AMPK, a multisubstrate enzyme activated by increase in AMP during metabolite stress caused by exercise, hypoxia, and lack of cell nutrients as well as hormones (15, 16, 18). We found that rosiglitazone activated the phosphorylation of AMPK in NSCLC cells. This fuel-sensing enzyme, which is an upstream signal of mTOR, plays a major role in the regulation of cellular lipid and protein metabolism in response to stimuli, such as exercise, changes in fuel availability, and the adipocyte-derived hormone leptin (13). Many cancers are characterized by increased expression and/or activity of enzymes that are inhibited by AMPK. Recent studies showed that activation of AMPK inhibits protein synthesis by phosphorylation of several important regulators. AMPK phosphorylation negatively regulated protein synthesis by directly phosphorylating and inhibiting mTOR (17). Rosiglitazone antagonized the stimulatory effects of androgen on fatty acid and protein synthesis in prostate cancer cells by down-regulating fatty acid synthesis, acetyl-COA carboxylase, and mTOR (15). The tumor suppressor LKB1 has been identified as an upstream activator of AMPK. Of note, rosiglitazone did not affect LKB1 expression in the current study, and this corresponds with other reports showing that an AMPK activator does not affect LKB1 expression (37, 38).

We also found that rosiglitazone inhibited the phosphorylation of p70S6K. The link between the AMPK and mTOR signaling pathway has been reported in other studies (15, 17, 39). AMPK activators, AICAR and rosiglitazone, inhibited p70S6K activity and phosphorylation in human corneal epithelial and other cancer cells (14, 15, 17, 18). The inhibition of protein synthesis by pharmacologic activation of AMPK may be a key regulatory mechanism by which hypertrophic growth can be controlled (40). Our results suggest that regulation of AMPK and p70S6K by rosiglitazone might contribute to growth inhibition of NSCLC cells.

As mentioned above, we found that the effects of rosiglitazone on phosphorylation of AMPK and p70S6K were not blocked by the PPAR{gamma} antagonist, suggesting that PPAR{gamma}-independent signals were involved. PPAR{gamma}-independent signals mediating the effect of rosiglitazone have been shown in several other studies (41–43). Galli et al. found that rosiglitazone and pioglitazone inhibit invasiveness of pancreatic cancer cells via PPAR{gamma}-independent mechanisms that involve metalloproteinases-2 and plasminogen activator inhibitor-1 expression (41). Shiau et al. (42) showed that the two prostate cancer cell lines PC-3 (PPAR{gamma} expressing) and LNCaP (PPAR{gamma} deficient) cells are sensitive to apoptosis induction by troglitazone and its PPAR{gamma}-inactive analogue irrespective of their PPAR{gamma} expression status. This is, in part, related to their ability to inhibit the antiapoptotic functions of Bcl-xL and Bcl-2 rather than through activation of the PPAR{gamma} signal.

We found that rosiglitazone enhanced the effect of the inhibitor of mTOR, rapamycin, in reducing NSCLC cell proliferation. The effect of rosiglitazone on cell growth was not completely blocked by the PPAR{gamma} antagonist GW9662 suggested that other signals were involved in mediating the effect of rosiglitazone on cell growth inhibition. The effect of rapamycin on reduction of cell growth was not affected by inactivation of PPAR{gamma} signal, suggesting that different signal pathways were involved. Interestingly, interfering with rosiglitazone-induced activation of AMPK by decreasing the expression of the enzyme using siRNA, abrogated, in part, the inhibitory effect of rosiglitazone on NSCLC cell growth, suggesting AMPK signal is also involved in the NSCLC cell growth inhibition by rosiglitazone. This finding is in agreement with other studies showing that the effects of rosiglitazone in increased glucose flux in skeletal muscle cells via activation of AMPK signal were blocked by the AMPK siRNA (44); in addition, the reduction of AMPK expression by AMPK siRNA reversed the inhibitory effects of AMPK activators, such as rosiglitazone and 15d-PGJ2, which are also PPAR{gamma} ligands, on inducible nitric oxide synthase expression and nitric oxide production in myocytes (45). In line with other studies showing that activation of AMPK inhibited growth of several types of cancer cells in vitro (14, 15, 46), these observations establish a causative role for AMPK in rosiglitazone-mediated inhibition of NSCLC cell growth.

Taken together, our observations show that rosiglitazone can inhibit NSCLC growth through PPAR{gamma}-dependent signals that inhibit Akt and stimulate PTEN. Through PPAR{gamma}-independent signals, rosiglitazone up-regulates AMPK, thereby down-regulating the mTOR/p70S6K pathway, which further contributes to growth inhibition (Fig. 7 ). These data provide insight into potentially additive interventions for anticancer therapies against NSCLC.


Figure 7
View larger version (9K):
[in this window]
[in a new window]
  		Figure 7. Schematic representation of the cell signaling events induced by rosiglitazone while inhibiting cell proliferation. A, this model shows that rosiglitazone, through inactivation of the phosphorylation of PI3K downstream signal Akt, while it increases PTEN via a PPAR{gamma}-dependent signal. B, rosiglitazone also activates the phosphorylation of AMPK and inhibits phosphorylation of p70S6K via PPAR{gamma}-independent signals and enhances NSCLC cell growth inhibition in the presence of the mTOR inhibitor rapamycin. Blocking AMPK pathway abrogated, in part, the inhibitory effects of rosiglitazone on NSCLC cell growth.

 

   Acknowledgments
 
We thank Dr. Neil Sidell for providing the CMX-PPAR{gamma}2 overexpression vector and Dr. Shi-Yong Sun (Department of Hematology and Oncology, Emory University, Atlanta, GA) for donating the H1792 NSCLC cells.


   Footnotes
 
Grant support: American Lung Association Research grant RG-10215N (S.W. Han) and Department of Veterans Affairs Merit Review Grant (J. Roman).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 8/29/05; revised 11/ 9/05; accepted 12/ 8/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004;94:1168–78.[Abstract/Free Full Text]
  2. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992;358:771–4.[CrossRef][Medline]
  3. Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, Heneka MT. Anti-inflammatory and antiproliferative actions of PPAR-{gamma} agonists on T lymphocytes derived from MS patients. J Leukoc Biol 2004;75:478–85.[Abstract/Free Full Text]
  4. Hirase N, Yanase T, Mu Y, et al. Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. Oncology 1999;57 Suppl 2:17–26.[Medline]
  5. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor {gamma} agonists. Lancet Oncol 2004;5:419–29.[CrossRef][Medline]
  6. Theocharis S, Kanelli H, Politi E, et al. Expression of peroxisome proliferator activated receptor-{gamma} in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer 2002;36:249–55.[CrossRef][Medline]
  7. Satoh T, Toyoda M, Hoshino H, et al. Activation of peroxisome proliferator-activated receptor-{gamma} stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene 2002;21:2171–80.[CrossRef][Medline]
  8. Han S, Sidell N, Fisher PB, Roman J. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor {gamma} in human lung carcinoma cells. Clin Cancer Res 2004;10:1911–9.[Abstract/Free Full Text]
  9. Keshamouni VG, Reddy RC, Arenberg DA, et al. Peroxisome proliferator-activated receptor-{gamma} activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004;23:100–8.[CrossRef][Medline]
  10. Li L, Ittmann MM, Ayala G, et al. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 2005;8:108–18.[CrossRef][Medline]
  11. Wang X, Beugnet A, Murakami M, Yamanaka S, Proud CG. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol Cell Biol 2005;25:2558–72.[Abstract/Free Full Text]
  12. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004;24:200–16.[Abstract/Free Full Text]
  13. Hardie DG. New roles for the LKB1->AMPK pathway. Curr Opin Cell Biol 2005;17:167–73.[CrossRef][Medline]
  14. Luo Z, Saha AK, Xiang X, Ruderman NB. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005;26:69–76.[CrossRef][Medline]
  15. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 2004;321:161–7.[CrossRef][Medline]
  16. Nagata D, Takeda R, Sata M, et al. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation 2004;110:444–51.[Abstract/Free Full Text]
  17. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002;277:25226–32.[Abstract/Free Full Text]
  18. Kimura N, Tokunaga C, Dalal S, et al. A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells 2003;8:65–79.[Abstract]
  19. Han S, Sidell N, Susan Roser-Pager S, Roman J. Fibronectin stimulates human lung cancer cell growth by inducing cyclooxygenase-2 (COX-2) gene expression. Int J Cancer 2004;111:322–31.[CrossRef][Medline]
  20. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK. Transcriptional activation by peroxisome proliferator-activated receptor {gamma} is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 1997;272:5128–32.[Abstract/Free Full Text]
  21. Han S, Inoue H, Flowers LC, Sidell N. Control of COX-2 gene expression through peroxisome proliferator-activated receptor {gamma} in human cervical cancer cells. Clin Cancer Res 2003;9:4627–35.[Abstract/Free Full Text]
  22. Han SW, Lei ZM, Rao CV. Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin during the differentiation of human endometrial stromal cells into decidua. Endocrinology 1996;137:1791–7.[Abstract]
  23. Jiang G, Dallas-Yang Q, Biswas S, Li Z, Zhang BB. Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor {gamma} (PPAR{gamma}), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo. Biochem J 2004;377:339–46.[CrossRef][Medline]
  24. Shao J, Sheng H, DuBois RN. Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 2002;62:3282–8.[Abstract/Free Full Text]
  25. Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-{gamma} ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 2005;65:772–81.[Abstract/Free Full Text]
  26. Ferruzzi P, Ceni E, Tarocchi M, et al. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 2005;90:1332–9.[Abstract/Free Full Text]
  27. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor {gamma} (PPAR {gamma}). J Biol Chem 1995;270:12953–6.[Abstract/Free Full Text]
  28. Valentiner U, Carlsson M, Erttmann R, Hildebrandt H, Schumacher U. Ligands for the peroxisome proliferator-activated receptor-{gamma} have inhibitory effects on growth of human neuroblastoma cells in vitro. Toxicology 2005;213:157–68.[CrossRef][Medline]
  29. Patel RK, Mohan C. PI3K/AKT signaling and systemic autoimmunity. Immunol Res 2005;31:47–55.[CrossRef][Medline]
  30. Kim D, Dan HC, Park S, et al. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 2005;10:975–84.[Medline]
  31. Farrow B, Evers BM. Activation of PPAR{gamma} increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 2003;301:50–3.[CrossRef][Medline]
  32. Vasudevan KM, Gurumurthy S, Rangnekar VM. Suppression of PTEN expression by NF-{kappa} B prevents apoptosis. Mol Cell Biol 2004;24:1007–21.[Abstract/Free Full Text]
  33. Leslie NR, Downes CP. PTEN function: how normal cells control it and tumour cells lose it. Biochem J 2004;382:1–11.[CrossRef][Medline]
  34. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. Tumor suppressor and anti-inflammatory actions of PPAR{gamma} agonists are mediated via upregulation of PTEN. Curr Biol 2001;11:764–8.[CrossRef][Medline]
  35. Morosetti R, Servidei T, Mirabella M, et al. The PPAR{gamma} ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int J Oncol 2004;25:493–502.[Medline]
  36. Sasaki T, Fujimoto Y, Tsuchida A, Kawasaki Y, Kuwada Y, Chayama K. Activation of peroxisome proliferator-activated receptor {gamma} inhibits the growth of human pancreatic cancer. Pathobiology 2001;69:258–65.[CrossRef][Medline]
  37. Sakamoto K, Goransson O, Hardie DG, Alessi DR. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am J Physiol Endocrinol Metab 2004;287:E310–7.[Abstract/Free Full Text]
  38. Lizcano JM, Goransson O, Toth R, et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 2004;23:833–43.[CrossRef][Medline]
  39. Krause U, Bertrand L, Hue L. Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes. Eur J Biochem 2002;269:3751–9.[Medline]
  40. Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 2004;279:32771–9.[Abstract/Free Full Text]
  41. Galli A, Ceni E, Crabb DW, et al. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPAR{gamma} independent mechanisms. Gut 2004;53:1688–97.[Abstract/Free Full Text]
  42. Shiau CW, Yang CC, Kulp SK, et al. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPAR{gamma}. Cancer Res 2005;65:1561–9.[Abstract/Free Full Text]
  43. Frohlich E, Machicao F, Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer 2005;12:291–303.[Abstract/Free Full Text]
  44. Konrad D, Rudich A, Bilan PJ, et al. Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells. Diabetologia 2005;48:954–66.[CrossRef][Medline]
  45. Pilon G, Dallaire P, Marette A. Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J Biol Chem 2004;279:20767–74.[Abstract/Free Full Text]
  46. Saitoh M, Nagai K, Nakagawa K, Yamamura T, Yamamoto S, Nishizaki T. Adenosine induces apoptosis in the human gastric cancer cells via an intrinsic pathway relevant to activation of AMP-activated protein kinase. Biochem Pharmacol 2004;67:2005–11.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
Z. Szocs, B. Brunmair, K. Stadlbauer, P. Nowotny, L. Bauer, A. Luger, and C. Furnsinn
Age-Dependent Development of Metabolic Derangement and Effects of Intervention with Pioglitazone in Zucker Diabetic Fatty Rats
J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 323 - 329.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Monami, C. Lamanna, N. Marchionni, and E. Mannucci
Rosiglitazone and Risk of Cancer: A meta-analysis of randomized clinical trials
Diabetes Care, July 1, 2008; 31(7): 1455 - 1460.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. E. Ramos-Nino and B. Littenberg
A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells
Mol. Cancer Ther., July 1, 2008; 7(7): 1871 - 1879.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. E. Milam, V. G. Keshamouni, S. H. Phan, B. Hu, S. R. Gangireddy, C. M. Hogaboam, T. J. Standiford, V. J. Thannickal, and R. C. Reddy
PPAR-{gamma} agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis
Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L891 - L901.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Y. Bren-Mattison, A. M. Meyer, V. Van Putten, H. Li, K. Kuhn, R. Stearman, M. Weiser-Evans, R. A. Winn, L. E. Heasley, and R. A. Nemenoff
Antitumorigenic Effects of Peroxisome Proliferator-Activated Receptor-{gamma} in Non-Small-Cell Lung Cancer Cells Are Mediated by Suppression of Cyclooxygenase-2 via Inhibition of Nuclear Factor-{kappa}B
Mol. Pharmacol., March 1, 2008; 73(3): 709 - 717.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
T. Tamguney and D. Stokoe
New insights into PTEN
J. Cell Sci., December 1, 2007; 120(23): 4071 - 4079.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Hasegawa, Y. Yamada, K. Komiyama, M. Hayashi, M. Ishibashi, T. Sunazuka, T. Izuhara, K. Sugahara, K. Tsuruda, M. Masuda, et al.
A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-{Delta}12, 14 prostaglandin J2 production
Blood, September 1, 2007; 110(5): 1664 - 1674.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. M. Hong, J. A. Belperio, M. P. Keane, M. D. Burdick, and R. M. Strieter
Differentiation of Human Circulating Fibrocytes as Mediated by Transforming Growth Factor-beta and Peroxisome Proliferator-activated Receptor {gamma}
J. Biol. Chem., August 3, 2007; 282(31): 22910 - 22920.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. Kopelovich, J. R. Fay, C. C. Sigman, and J. A. Crowell
The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention
Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1330 - 1340.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
F.-S. Chou, P.-S. Wang, S. Kulp, and J. J. Pinzone
Effects of Thiazolidinediones on Differentiation, Proliferation, and Apoptosis
Mol. Cancer Res., June 1, 2007; 5(6): 523 - 530.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
D. Shen, C. Deng, and M. Zhang
Peroxisome proliferator-activated receptor {gamma} agonists inhibit the proliferation and invasion of human colon cancer cells
Postgrad. Med. J., June 1, 2007; 83(980): 414 - 419.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
K. R. Laderoute, K. Amin, J. M. Calaoagan, M. Knapp, T. Le, J. Orduna, M. Foretz, and B. Viollet
5'-AMP-Activated Protein Kinase (AMPK) Is Induced by Low-Oxygen and Glucose Deprivation Conditions Found in Solid-Tumor Microenvironments.
Mol. Cell. Biol., July 1, 2006; 26(14): 5336 - 5347.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
F. Lin, P. L. Zhang, X. J. Yang, J. W. Prichard, M. Lun, and R. E. Brown
Morphoproteomic and Molecular Concomitants of an Overexpressed and Activated mTOR Pathway in Renal Cell Carcinomas
Ann. Clin. Lab. Sci., January 1, 2006; 36(3): 283 - 293.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted